Amryt Pharma (AMYT) has announced results for the six months ended 30 June 2017. There were no great shocks the buy case is compelling and low risk - my target, for shares I admit to owning, is very conservative. Others are twice as ambitious or more!
on ShareProphets | CommentsFiled under: